Trial results set up Keenova to gain 3rd indication for Xiaflex
Trial results set up Keenova to gain 3rd indication for Xiaflex (Fierce Pharma.)
Keenova
Private
Keenova is the specialty therapeutics subsidiary formed to commercialize Xiaflex (collagenase clostridium histolyticum) for Dupuytren's contracture and Peyronie's disease following Endo International's bankruptcy-related restructuring.
Company Info
Sector:Specialty Pharmaceuticals / Orphan Therapeutics
Headquarters:Malvern, Pennsylvania, USA
Founded:2024
Website:www.keenova.com/
Recent News
Leadership Team
Careers & Job Openings